Terpenoids and Aromatic Compounds from the New Zealand Liverworts *Plagiochila*, *Schistochila*, and *Heteroscyphus* Species

Fumihiro NAGASHIMA,* Takashi SEKIGUCHI, Shigeru TAKAOKA, and Yoshinori ASAKAWA

Faculty of Pharmaceutical Sciences, Tokushima Bunri University; Yamashiro-cho, Tokushima 770–8514, Japan.

Received December 1, 2003; accepted January 19, 2004

A new clerodane- and two new *ent*-rosane-type diterpenoids have been isolated from the New Zealand liverworts *Heteroscyphus billardieri* and *Plagiochila deltoidea*, respectively. The known bisbibenzyl compounds and acetophenones have also been isolated from *Schistochila glaucescens* and *Plagiochila fasciculata*. Their structures were established by extensive NMR techniques. Chemosystematics of the *Plagiochila* species have been discussed.

Key words *Heteroscyphus billardieri*; *Plagiochila deltoidea*; *Plagiochila fasciculata*; *Schistochila glaucescens*; *ent*-rosane-type diterpene; bisbibenzyl

A number of secondary metabolites possessing novel carbon skeletons have been isolated from liverworts, several of which show interesting biological activities.^{1,2)} The majority of these compounds are lipophilic terpenoids and phenolics. These compounds are also often valuable as chemosystematic and genetic markers.^{1,2)} For the purpose of searching for novel compounds and their biological activity, we are currently studying the chemical constituents of New Zealand liverworts.^{3,4)} A number of endemic liverwort genera have been found in New Zealand, which are not related to those found in Japan.⁵⁾

Four New Zealand liverworts, *Heteroscyphus billardieri* (SCHWAEGR.) SCHNIFEN., *Plagiochila deltoidea* LINDENB., *Plagiochila fasciculata* LINDENB., and *Schistochila glaucescens* (HOOK.) STEPH., were further chemically analyzed to give three new diterpenoids: clerodane- (**1**) and *ent*-rosane-type (**2**, **3**); three known terpenoids: *ent*-pimarane-type diterpenoid (**4**), lupane-type triterpenoid (**5**) and aromadendrane-type sesquiterpenoid (**6**); and six known aromatic compounds: acetophenones (**7**, **8**) and bisbibenzyls (**9**–**12**). Here, we report on the isolation and structural characterization of the new compounds and chemosystematics of two *Plagiochila* species.

Results and Discussion

A combination of chromatography on silica gel, Sephadex LH-20 and preparative HPLC of the ether extract of *H. billardieri* belonging to the Geocalycaceae resulted in the isolation of compound **1**.

The IR spectrum of compound **1** showed the presence of a hydroxy group (3440 cm⁻¹), and its high-resolution electron impact mass spectrometry (HR-EI-MS) clarified the molecular formula as C₂₀H₃₂O (obs. *m/z* 288.2455 [M]⁺). The ¹H-NMR spectrum (Table 1) showed the presence of three tertiary methyls, a secondary methyl, an oxygenated methine proton and a vinyl group. The ¹³C-NMR (Table 2) and its distortionless enhancement by polarization transfer (DEPT) spectra indicated the presence of two trisubstituted olefinic carbons (δ 122.5 d, 128.8 d, 135.2 s, 143.5 s), vinyl carbons (δ 110.5 t, 141.9 d), a methine (δ 75.4) bearing a secondary hydroxy group, and also five methyls, four methylenes, two methines and two quaternary carbons, respectively. From the above spectral evidence, compound **1** was suggested to be a bicyclic diterpenoid. Successively, the analysis of ¹H–¹H correlated spectroscopy (¹H–¹H COSY), the heteronuclear multiple quantum coherence (HMQC) and the heteronuclear multiple bond correlation (HMBC) spectra of **1**, as shown in

* To whom correspondence should be addressed. e-mail: fnaga@ph.bunri-u.ac.jp

Table 1. ^1H -NMR Spectral Data of **1**–**3** (600 MHz, CDCl_3)

H	1	2	3
1	1.53—1.63 2H, m	5.39 quint. like (2.5)	5.39 quint. like (2.2)
2	2.02 br d (17.9) ^a , α 1.89 m, β 5.22 br s	1.92 dddd (17.0, 10.4, 4.1, 2.5), α 2.29 dddd (17.0, 5.8, 5.8, 2.5), β 3.51 dd (10.4, 5.8)	1.91 dddd (17.0, 10.4, 4.1, 2.2), α 2.28 dddd (17.0, 5.8, 5.8, 2.2), β 3.50 dd (10.4, 5.8)
5		2.14 d sept. (13.7, 2.5)	2.12 d sept. like (14.0, 2.2)
6	3.53 dt (10.2, 4.9)	1.35 m, α 1.70 m, β	1.34 m, α 1.66—1.73 m, β
7	1.47 ddd (13.5, 13.5, 11.3), α 1.53—1.63 m, β 1.53—1.63 m	1.23—1.28 m, α 1.58 m, β 1.72 m	1.22—1.28 m, α 1.59 m, β 1.66—1.73 m
10	1.30 dd (11.8, 2.2)		
11	2.14 dd (15.7, 8.0) 2.20 dd (15.7, 8.0)	1.67 m, α 1.43 ddd (13.7, 13.7, 3.6), β 1.51 ddd (13.7, 13.7, 3.6), α	1.66—1.73 m 1.36—1.46 m 1.36—1.46 m, α
12	5.42 t (8.0)	1.23—1.28 m, β	1.13 m, β
14	6.37 dd (17.9, 11.0)	1.19 t (13.5), α 1.11 ddd (13.5, 3.8, 2.7), β 5.81 dd (17.6, 10.7)	1.22—1.28 m, α 1.08 ddd (13.2, 3.6, 2.5), β 2.70 dd (3.8, 3.0)
15	4.93 d (11.0) 5.07 d (17.9)		
16	1.75 s	4.85 dd (10.7, 1.6) 4.92 dd (17.6, 1.6)	2.62 dd (4.9, 3.8) 2.65 dd (4.9, 3.0)
17	0.86 d (6.3)	0.98 s	0.89 s
18	1.83 s	1.02 s	1.01 s
19	1.02 s	0.67 s	0.66 s
20	0.76 s	0.91 s	0.91 s

^a) Coupling constants (J in Hz) are given in parentheses.Table 2. ^{13}C -NMR Spectral Data of **1**–**3** and **15**

C	1 ^a	2 ^b	3 ^a	15 ^b
1	18.2	115.2	115.4	115.0
2	26.7	31.9	31.8	38.2
3	122.5	75.1	75.0	214.5
4	143.5	36.9	36.9	46.5
5	44.0	43.6	43.6	44.5
6	75.4	18.6	18.5	18.4
7	37.9	25.7	25.7	25.3
8	35.1	31.5	31.0	31.2
9	40.1	37.0	37.1	37.3
10	46.3	148.9	148.6	148.8
11	36.7	35.3	34.7	34.4
12	128.8	32.9	28.1	27.9
13	135.2	36.4	33.3	33.4
14	141.9	39.8	37.2	37.4
15	110.5	151.3	61.0	61.0
16	11.9	108.7	43.4	43.4
17	16.0	22.3	19.4	19.2
18	22.4	23.9	23.8	20.6
19	14.8	12.9	12.8	19.4
20	17.4	20.8	20.7	20.3

Measured in CDCl_3 , a) at 150 MHz, b) at 100 MHz.Table 3. ^{13}C -NMR of Compounds **10** and **19** (150 MHz, CDCl_3)

C	10	19	C	10	19
1	153.4	153.1	10'	113.5	114.2
2	120.2	120.7	11'	159.6	159.0
3	130.1	130.1	12'	115.3	115.4
4	137.3	137.1	13'	129.8	129.6
5	130.1	130.1	14'	120.9	121.1
6	120.2	120.7	1''	40.8	41.5
7	33.05	33.6	2''	18.5	18.7
8	30.7	29.5	3''	41.9	42.1
9	126.5	125.8	4''	32.99	33.1
10	143.6	144.7	5''	48.9	48.8
11	137.9	135.5	6''	21.4	21.4
12	142.4	142.4	7''	156.1	156.5
13	116.6	114.6	8''	103.7	103.9
14	123.4	123.4	9''	40.0	41.1
1'	138.4	138.1	10''	33.5	34.0
2'	150.8	150.8	11''	82.0	81.0
3'	117.2	116.7	12''	101.1	100.3
4'	141.4	141.5	13''	19.3	19.5
5'	121.2	121.1	14''	32.5	21.6
6'	122.9	122.8	15''	21.6	32.7
7'	40.3	40.1	OAc	20.7	20.7
8'	41.8	40.6		169.0	169.1
9'	143.5	143.9			

Fig. 1, clarified that the structure of **1** could be a clerodane-type diterpenoid with a hydroxy group at C-6. Moreover, the phase sensitive nuclear Overhauser enhancement and exchange spectroscopy (NOESY) spectrum (Fig. 1) of **1** determined that the configuration of the hydroxy group at C-6 is α . Thus, the structure of **1** was established as 6 α -hydroxy-3,12 E ,14-clerodatriene.

Two new *ent*-rosane-type diterpenoids, **2** and **3**, and the previously known diterpenoid acanthoic acid (**4**)⁶ were isolated from the ether extract of *P. deltoidea*. The known methyl ester (**5**) of betulinic acid (**13**)⁷ was also isolated

from the methylated fraction with trimethylsilyldiazomethane. The structures of known compounds **4** and **5** were determined by comparison with their reference spectral data.^{6,7}

The IR spectrum of **2** confirmed the presence of a hydroxy group (3390 cm^{-1}). The molecular formula was found to be $\text{C}_{20}\text{H}_{32}\text{O}$ (obs. m/z 288.2455) by HR-EI-MS, indicating five degrees of unsaturation. The ^1H - and ^{13}C -NMR spectra (Tables 1, 2) of **2** showed the presence of a trisubstituted double bond (δ 115.2 d, 148.9 s), a terminal vinyl group (δ 108.7 t,

Fig. 1. The ^1H - ^1H (Bold Lines), Long-Range ^1H - ^{13}C (Arrows), and NOE Correlations (Half Arrows) of **1**

Fig. 2. The ^1H - ^1H (Bold Lines), Long Range ^1H - ^{13}C (Arrows), and NOE Correlations (Half Arrows) of **2**

151.3 d) and an oxygenated methine (δ 75.1), as well as four methyls, six methylenes, two methines and three quaternary carbons, respectively. These spectral data supported that compound **2** was a tricyclic diterpenoid. The ^1H - ^1H COSY (Fig. 2) of **2** confirmed the presence of four partial structures: i) $-\text{C}=\text{CH}-\text{CH}_2-\text{CH}(\text{OH})-$, ii) $-\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}-\text{CH}_2-$, iii) $-\text{CH}_2-\text{CH}_2-$, and iv) $-\text{CH}=\text{CH}_2$. The connectivity of each partial structure was clarified by the HMBC spectrum, as shown in Fig. 2. Accordingly, the structure of **2** was supported to be a rosane-type diterpenoid with the hydroxy group at C-3. Its stereochemistry was determined by NOESY spectrum, as shown in Fig. 2. Thus, the stereostructure of **2** was clarified to be 1(10),15-rosadien-3 α -ol. Furthermore, the absolute configuration of **2** was established as (3*R*)-*ent*-1(10),15-rosadien-3-ol by X-ray crystallographic analysis of the *m*-bromobenzoate derivative **14**, as shown in Fig. 3.

The EI-MS spectrum of compound **3** showed a molecular ion peak at m/z 304 $[\text{M}]^+$, and its IR spectrum displayed the presence of a hydroxy (3436 cm^{-1}) group. The ^1H - and ^{13}C -NMR (Tables 1, 2) were similar to those of compound **2** except for the absence of a terminal vinyl group. Therefore, its structure was suggested to be a rosane-type diterpenoid. The HR-EI-MS showed the molecular formula $\text{C}_{20}\text{H}_{32}\text{O}_2$ (obs. m/z 304.2404 $[\text{M}]^+$), indicating five degrees of unsaturation. Oxidation of **3** gave a ketone **15** which showed only the presence of a carbonyl group (1714 cm^{-1}) in the IR spectrum,

Fig. 3. The ORTEP Drawing of **14**

Anisotropic ellipsoids are represented by a 50% probability level.

Fig. 4. The NOE Correlations of **3**

suggesting compound **3** possessed a hydroxy and an epoxy group in the molecule. Furthermore, the structure of **3** was clarified to be 15,16-epoxy-1(10)-rosen-3-ol by detailed analysis of ^1H - ^1H COSY, HMQC and HMBC spectra. The NOESY spectrum revealed the stereochemistry of **3** to be as shown in Fig. 4. In order to determine the absolute configuration, the esterification of compound **3** with *p*-bromobenzoyl chloride was carried out to give a *p*-bromobenzoate (**16**) with chlorine at C-16. The X-ray crystallographic analysis of **16** gave the ORTEP drawing shown in Fig. 5. Thus, the absolute configuration of **3** was established as (3*R*,15*R*)-*ent*-15,16-epoxy-1(10)-rosen-3-ol.

Three known compounds, *ent*-spathulenol (**6**),⁸ 2-hydroxy-3,4,6-trimethoxy acetophenone (**7**)⁹ and 2-hydroxy-4,6-dimethoxy acetophenone (**8**)¹⁰ were isolated from the ether extract of *P. fasciculata*. The structures of these compounds were determined by comparison with an authentic sample or reference spectral data. Compounds **7** and **8** have already been isolated from *P. fasciculata* collected from different locations in New Zealand by Perry *et al.*¹¹

Previously we reported the isolation of novel macrocyclic bisbibenzyls neomarchantins A (**12**) and B (**17**), and marchantin C (**11**) from *S. glaucescens*.¹² Further fractionation of the ether extract of *S. glaucescens* collected from various locations resulted in the isolation of two sesquiterpene-bisbibenzyl compounds **9** and **18**, together with two known bisbibenzyls, marchantin C (**11**)¹³ and neomarchantin A (**12**),¹² and stigmasterol. The determination of compounds **11** and **12** were confirmed by comparison with ^1H - and ^{13}C -

Fig. 5. The ORTEP Drawing of **16**

Anisotropic ellipsoids are represented by a 50% probability level.

NMR of authentic samples. The structure of **9** was also determined by comparison with those of reference spectral data.¹⁴ The presence of compound **18** was confirmed as its acetate (**10**) isolated from the acetylated fraction of a mixture of compounds **9** and **18**. Almost at the same time, Perry *et al.* reported the same compounds **9** and **18** from the same liverwort collected in a different location in New Zealand independently, and named *glaucescens* bisbibenzyl (GBB) A (**9**) and B (**18**).¹⁴

Heteroscyphus species produce calamenene- and 2,3-secoaromadendrane-type sesquiterpenoids, or clerodane- and neoverrucosane-type diterpenoids. The present *H. billardieri* elaborates a clerodane-type diterpenoid; however, calamenene- and 2,3-secoaromadendrane-type sesquiterpenoids could not be identified in the present species.

The number of species assigned to the genus *Plagiochila* is more than 1600. Of these, about 60 species have been investigated chemically and classified into five main chemotypes: i) 2,3-secoaromadendrane-type, ii) other sesquiterpenoid-type, iii) bibenzyl-type, iv) sesquiterpene lactone-type, and v) cyclic bisbibenzyl-type.² Reporting on the isolation of diterpenoids from *Plagiochila* species is rare.^{1,2} The present *P. deltoidea* produces *ent*-rosane- and *ent*-pimarane-type diterpenoids as main components. This is the first report of the isolation of *ent*-rosane- and *ent*-pimarane-type diterpenoids from *Plagiochila* species. Acetophenone derivatives are also rare secondary metabolites of liverworts.^{1,2} The present *P. fasciculata* produces two acetophenones, **7** and **8**, as main components. Thus, *P. deltoidea* and *P. fasciculata* are classified into different chemo-types in the *Plagiochila* species.

Experimental

Optical rotations were measured on a Jasco DIP-1000 polarimeter. IR spectra were recorded on a Jasco FT/IR-5300 infrared spectrophotometer. UV spectra were recorded on a Shimadzu UV-1650PC UV-visible spectrophotometer. CD spectra were recorded on a Jasco J-725 spectropolarimeter. The ¹H- and ¹³C-NMR spectra were measured on Varian Unity-600 (¹H; 600 MHz, ¹³C; 150 MHz) and JEOL Eclipse-400 (¹H; 400 MHz, ¹³C; 100 MHz) instruments. Chemical shift values are expressed in δ (ppm) downfield from tetramethylsilane as an internal standard (¹H-NMR), and in δ 77.03 (ppm) from CDCl₃ as a standard (¹³C-NMR). Mass spectra were ob-

tained on a JEOL JMS AX-500 instrument. X-Ray crystallographic analysis was carried out on a Mac Science DIP-2020 instrument. TLC was carried out using Silica gel 60F₂₅₄ plates (Merck). Column chromatography was performed on Silica-gel 60 (Merck, 230–400 and 35–70 mesh) and Sephadex LH-20 (Amersham Pharmacia Biotech, sol. CH₂Cl₂–MeOH 1:1). TLC plates were examined under UV (254 nm) light, and by spraying with 30% H₂SO₄ or Godin reagent,¹⁵ followed by heating.

Plant Material *Schistochila glaucescens* (HOOK.) STEPH. (NZ-109), *Plagiochila deltoidea* LINDENB. (NZ-128), *Plagiochila fasciculata* LINDENB. (NZ-134), and *Heteroscyphus billardieri* (SCHWAEGR.) SCHNIFF. (NZ-127), were collected from Sewell Peak, Ohakune, Te Aroha and Haast in New Zealand, 2000, respectively, and identified by J. E. Braggins (The University of Auckland). Their voucher specimens were deposited at the Faculty of Pharmaceutical Sciences, Tokushima Bunri University.

Extraction and Isolation The ether extract (148 mg) of *H. billardieri* was divided into nine fractions by column chromatography (CC) on silica gel using an *n*-hexane–EtOAc gradient solvent system. 6 α -Hydroxy-3,12*E*,14-clerodatriene (**1**, 2 mg) was isolated from Fr. 2 by preparative TLC (*n*-hexane–EtOAc 4:1).

6 α -Hydroxy-3,12*E*,14-clerodatriene (**1**): [α]_D²⁰ –40.9° (*c*=0.13, CHCl₃). FT-IR cm^{–1}: 3440. UV $\lambda_{\max}$ (MeOH) nm (log ϵ): 232 (3.87). ¹H- and ¹³C-NMR: Tables 1 and 2. HR-EI-MS *m/z*: 288.2455 (Calcd for C₂₀H₃₂O: 288.2454). EI-MS *m/z* (int.): 288 [M]⁺ (1), 207 (46), 189 (100), 149 (9), 135 (64), 119 (17), 109 (41), 95 (57), 81 (67), 69 (11), 57 (13), 55 (13).

The ether extract (611 mg) of *P. deltoidea* was divided into six fractions by column chromatography (CC) on silica gel using an *n*-hexane–EtOAc gradient solvent system. Fr. 3 was rechromatographed on silica gel and preparative HPLC (CHEMCOSORB 5Si-U, *n*-hexane–EtOAc 9:1) to afford (3*R*)-*ent*-1(10),15-rosadien-3-ol (**2**, 20.7 mg). (3*R*,15*R*)-*ent*-15,16-Epoxy-1(10)-rosen-3-ol (**3**, 37.8 mg) and acanthoic acid (**4**, 10.3 mg) were isolated from fr. 4 by Sephadex LH-20, silica gel and finally preparative HPLC (CHEMCOSORB 5Si-U, *n*-hexane–EtOAc 17:3). Fr. 5 was chromatographed on Sephadex LH-20 and silica gel to give five fractions. The third fraction, which was esterified with trimethylsilyldiazomethane, followed by preparative HPLC (CHEMCOSORB 5Si-U, *n*-hexane–EtOAc 17:3) gave methyl betulinate (**5**, 5.6 mg).

(3*R*)-*ent*-1(10),15-Rosadien-3-ol (**2**): [α]_D²⁰ +3.9° (*c*=1.91, CHCl₃). FT-IR cm^{–1}: 3390. ¹H- and ¹³C-NMR: Tables 1 and 2. HR-EI-MS *m/z*: 288.2455 (Calcd for C₂₀H₃₂O: 288.2454). EI-MS *m/z* (int.): 288 [M]⁺ (49), 273 (62), 270 (99), 255 (100), 216 (64), 201 (56), 187 (23), 173 (20), 159 (22), 145 (24), 138 (82), 135 (37), 133 (40), 121 (32), 119 (34), 109 (33), 105 (50), 93 (40), 81 (44), 80 (33), 67 (21), 55 (25), 41 (21).

(3*R*,15*R*)-*ent*-15,16-Epoxy-1(10)-rosen-3-ol (**3**): [α]_D²⁰ –4.9° (*c*=0.78, CHCl₃). FT-IR cm^{–1}: 3436. ¹H- and ¹³C-NMR: Tables 1 and 2. HR-EI-MS *m/z*: 304.2404 (Calcd for C₂₀H₃₂O₂: 304.2402). EI-MS *m/z* (int.): 304 [M]⁺ (45), 286 (100), 271 (94), 232 (44), 201 (24), 173 (22), 159 (20), 145 (23), 138 (49), 133 (32), 119 (31), 105 (38), 93 (29), 81 (19), 79 (17), 67 (12), 55 (15), 41 (13).

The ether extract (535 mg) of *P. fasciculata* was divided into eight fractions by column chromatography (CC) on silica gel using an *n*-hexane–EtOAc gradient solvent system. Fr. 5 was subjected to Sephadex LH-20 CC to yield 2-Hydroxy-3,4,6-trimethoxy acetophenone (**7**, 58.3 mg) and a mixture of sesquiterpenoid fractions. The mixture of sesquiterpenoid fractions was subjected to preparative HPLC (CHEMCOSORB 5-ODS-H, CH₃CN) to give *ent*-spatululenol (**6**, 4.2 mg). Fr. 7 was applied to Sephadex LH-20 and silica gel CC (*n*-hexane–EtOAc 4:1) to yield 2-hydroxy-4,6-dimethoxy acetophenone (**8**, 28.8 mg).

The ether extract (874 mg) of *S. glaucescens* was divided into seven fractions by CC on silica gel using an *n*-hexane–EtOAc gradient solvent system. Fr. 3 was chromatographed on Sephadex LH-20, silica gel and preparative HPLC (CHEMCOSORB 5-ODS-H, MeOH) to afford GBB A (**9**, 4.2 mg), stigmaterol (3.7 mg), and a mixture of GBB A (**9**) and B (**18**) fraction. The mixture of compounds **9** and **18** was acetylated with pyridine (2 ml) and acetic anhydride (2 ml), followed by purification by preparative HPLC (CHEMCOSORB 5-ODS-H, MeOH) after the solvents were removed, to yield GBB A acetate (**19**, 4.9 mg) and GBB B acetate (**10**, 10 mg). Marchantin C (**11**, 4.6 mg) and neomarchantin A (**12**, 11.5 mg) were isolated from fr. 4 by CC on Sephadex LH-20, silica gel and prep. HPLC (CHEMCOSORB 5Si-U, *n*-hexane–EtOAc 17:3).

GBB A acetate (**19**): [α]_D¹⁹ –100.6° (*c*=0.49, CHCl₃). FT-IR cm^{–1}: 1766, 1263. UV $\lambda_{\max}$ (EtOH) nm (log ϵ): 272 (3.84), 279 (3.79). ¹H-NMR (600 MHz, CDCl₃): δ 6.93 (2H, d, *J*=8.5 Hz, H-2 and H-6), 7.11 (2H, d, *J*=8.5 Hz, H-3 and H-5), 3.06 (1H, m, H-7), 3.11 (1H, m, H-7), 2.90 (1H, m, H-8), 3.16 (1H, m, H-8), 6.51 (1H, d, *J*=8.5 Hz, H-13), 6.55 (1H, d,

$J=8.5$ Hz, H-14), 6.29 (1H, d, $J=1.9$ Hz, H-3'), 6.78 (1H, d, $J=7.4$ Hz, H-5'), 6.97 (1H, d, $J=8.2$ Hz, H-6'), 2.46–2.51 (2H, m, H-7' and H-8'), 2.54–2.61 (2H, m, H-7' and H-8'), 6.18 (1H, dd, $J=2.5$, 1.6 Hz, H-10'), 7.05 (1H, dd, $J=8.2$, 2.7, 0.8 Hz, H-12'), 7.21 (1H, t, $J=8.2$ Hz, H-13'), 6.77 (1H, dd, $J=8.2$, 1.9 Hz, H-14'), 1.20 (1H, m, H-1'' α), 1.61 (1H, br d, $J=17.0$ Hz, H-1'' β), 1.44 (1H, m, H-2'' α), 1.55 (1H, m, H-2'' β), 1.16 (1H, m, H-3'' α), 1.42 (1H, m, H-3'' β), 1.25 (1H, dd, $J=12.1$, 4.9 Hz, H-5''), 2.11 (1H, dd, $J=17.3$, 4.4 Hz, H-6'' α), 1.81 (1H, m, H-6'' β), 1.90 (1H, br d, $J=15.7$ Hz, H-9'' α), 1.82 (1H, d, $J=15.7$ Hz, H-9'' β), 5.20 (1H, dd, $J=6.6$, 2.5 Hz, H-11''), 6.06 (1H, d, $J=6.6$ Hz, H-12''), 0.87 (3H, s, H-13''), 0.84 (3H, s, H-14''), 0.74 (3H, s, H-15''), 2.32 (3H, s, OCOCH₃). ¹³C-NMR: Table 3. HR-EI-MS m/z : 698.3238 (Calcd for C₄₅H₄₆O₇: 698.3244). EI-MS m/z (rel. int.): 698 (M⁺, 49), 656 (5), 628 (1), 532 (2), 482 (11), 440 (34), 410 (5), 303 (8), 275 (3), 218 (27), 213 (22), 133 (3), 123 (9), 94 (100), 77 (7), 69 (4), 43 (9).

GBB B acetate (**10**) [α]_D²⁰ +69.1° ($c=1.00$, CHCl₃). FT-IR cm⁻¹: 1767, 1275, 1262. UV $\lambda_{\max}$ (EtOH) nm (log ϵ): 273 (3.87), 281 (3.83). ¹H-NMR (600 MHz, CDCl₃): δ 6.93 (2H, d, $J=8.2$ Hz, H-2 and H-6), 7.18 (2H, d, $J=8.2$ Hz, H-3 and H-5), 3.12 (1H, dt, $J=14.3$, 4.9 Hz, H-7), 3.21 (1H, ddd, $J=14.3$, 11.5, 4.4 Hz, H-7), 2.84 (1H, m, H-8), 3.33 (1H, brs, H-8), 6.51 (1H, d, $J=8.5$ Hz, H-13), 6.41 (1H, d, $J=8.5$ Hz, H-14), 6.34 (1H, d, $J=1.9$ Hz, H-3'), 6.80 (1H, d, $J=8.0$ Hz, H-5'), 6.97 (1H, d, $J=8.0$ Hz, H-6'), 2.27–2.34 (2H, m, H-7' and H-8'), 2.73–2.82 (2H, m, H-7' and H-8'), 6.12 (1H, dd, $J=2.5$, 1.9 Hz, H-10'), 7.03 (1H, ddd, $J=8.2$, 2.5, 0.8 Hz, H-12'), 7.22 (1H, t, $J=8.2$ Hz, H-13'), 6.79 (1H, dd, $J=8.2$, 1.9 Hz, H-14'), 1.25–1.31 (3H, m, H-1'' α , H-2'' β and H-3'' α), 0.60 (1H, m, H-1'' β), 1.42 (1H, m, H-2'' α), 0.91 (1H, m, H-3'' β), 0.96 (1H, dd, $J=12.1$, 4.9 Hz, H-5''), 1.84 (1H, brt, $J=14.6$ Hz, H-6'' α), 2.15 (1H, dd, $J=17.3$, 3.3 Hz, H-6'' β), 1.39 (1H, d, $J=15.9$ Hz, H-9'' α), 1.08 (1H, br d, $J=15.9$ Hz, H-9'' β), 5.32 (1H, dd, $J=7.4$, 2.7 Hz, H-11''), 6.28 (1H, d, $J=7.4$ Hz, H-12''), 0.73 (3H, s, H-13''), 0.59 (3H, s, H-14''), 0.78 (3H, s, H-15''), 2.31 (3H, s, OCOCH₃). ¹³C-NMR: Table 3. HR-EI-MS m/z : 698.3243 (Calcd for C₄₅H₄₆O₇: 698.3244). EI-MS m/z (rel. int.): 698 (M⁺, 100), 656 (9), 532 (2), 482 (5), 440 (15), 410 (4), 328 (8), 303 (7), 218 (24), 213 (14), 147 (3), 123 (8), 109 (8), 94 (57), 69 (4), 43 (4).

***m*-Bromobenzoylation of 2** To a solution of compound **2** (8 mg) in dry CH₂Cl₂ (5 ml), *m*-bromobenzoic acid (48 mg), 1,3-dicyclohexylcarbodiimide (DCC, 52 mg), and 4-dimethylaminopyridine (DMAP, 24 mg) were added and kept at room temperature overnight, then purified by CC on silica gel (*n*-hexane–EtOAc 1 : 1) to afford *m*-bromobenzoate **14** (12.5 mg).

***m*-Bromobenzoate 14:** ¹H-NMR (400 MHz, CDCl₃): δ 0.89 (3H, s), 0.94 (3H, s), 0.99 (3H, s), 1.00 (3H, s), 2.11 (1H, m), 2.33 (1H, br d), 2.46 (1H, ddd, $J=16.8$, 5.9, 5.9, 2.2 Hz), 4.85 (1H, dd, $J=10.6$, 1.1 Hz), 4.93 (1H, dd, $J=17.6$, 1.1 Hz), 5.00 (1H, dd, $J=10.6$, 6.2 Hz), 5.43 (1H, t, $J=2.6$ Hz), 5.82 (1H, dd, $J=17.6$, 11.0 Hz), 7.33 (1H, t, $J=7.7$ Hz), 7.69 (1H, d, $J=8.1$ Hz), 7.99 (1H, d, $J=8.1$ Hz), 8.17 (1H, t, $J=1.8$ Hz, H-11). FAB-MS (*m*-NBA) m/z : 495 [M+2+Na]⁺, 493 [M+Na]⁺; (*m*-NBA+KCl) m/z 511 [M+2+K]⁺, 509 [M+K]⁺. EI-MS m/z (int.): 270 (100), 255 (35), 199 (5), 185 (25), 134 (17), 120 (78), 108 (54), 81 (17), 55 (9), 41 (6). Crystal data: C₂₇H₃₅BrO₂, Mr=471.484, Orthorhombic, $P2_12_12_1$, $a=6.3190(3)$ Å, $b=11.3430(8)$ Å, $c=33.884(3)$ Å, $\alpha=90.00^\circ$, $\beta=90.00^\circ$, $\gamma=90.00^\circ$, $V=2428.7(3)$ Å³, MoK α radiation, $\lambda=0.71073$, DIP Image plate, refinement on F^2 , full matrix least squares refinement, $R(\text{gt})=0.041$, $wR(\text{gt})=0.074$, $S(\text{gt})=0.937$, 2111 reflections, 272 parameters, only coordinates of H atoms refined, calculated weights sigma, cell refinement: Scalepack (HKL), data reduction: maXus, program used to refine structure: maXus.

Oxidation of 3 To a suspension of compound **3** (6.5 mg) in CH₂Cl₂ (2 ml) was added pyridinium chlorochromate (PCC, 8 mg), and the mixture was stirred for 1.5 h at room temperature. The reaction residue was chromatographed on silica gel (*n*-hexane–EtOAc 4 : 1) to give a ketone **15** (5.7 mg).

15,16-Epoxy-ent-1(10)-rosen-3-one (**15**): [α]_D²⁰ +6.7° ($c=0.12$, CHCl₃). FT-IR cm⁻¹: 1714. CD (EtOH): $\Delta\epsilon_{295\text{nm}}$ -0.68, $\Delta\epsilon_{221\text{nm}}$ -0.53. ¹H-NMR (600 MHz, CDCl₃): δ 0.88 (3H, s, H-17), 1.00 (3H, s, H-20), 1.03 (3H, s, H-19), 1.07 (3H, s, H-18), 1.12 (1H, m, H-14 β), 1.15 (1H, m, H-12 β), 1.29 (1H, m, H-14 α), 1.32 (1H, m, H-7), 1.41–1.47 (2H, m, H-11 β , H-12 α),

1.59–1.68 (4H, m, H-6, H-6, H-7, H-8), 1.73 (1H, m, H-11 α), 2.48 (1H, br d, $J=12.9$ Hz, H-5), 2.64 (1H, t, $J=4.7$ Hz, H-16), 2.66 (1H, dd, $J=4.7$, 3.0 Hz, H-16), 2.71 (1H, dd, $J=3.8$, 3.0 Hz, H-15), 2.75 (1H, ddd, $J=21.2$, 3.8, 2.7 Hz, H-2 β), 3.07 (1H, dt, $J=21.2$, 3.3 Hz, H-2 α), 5.52 (1H, q, $J=3.6$ Hz, H-1). ¹³C-NMR: Table 2. HR-EI-MS m/z : 302.2245 (Calcd for C₂₀H₃₀O₂: 302.2246). EI-MS m/z (int.): 302 [M]⁺ (100), 287 (51), 232 (16), 217 (12), 201 (19), 173 (21), 159 (17), 136 (80), 119 (28), 107 (30), 93 (35), 77 (27), 55 (16), 41 (17).

***p*-Bromobenzoylation of 3** To a solution of compound **3** (14.5 mg) in CH₂Cl₂ (2 ml) and pyridine (1 ml), *p*-bromobenzoic acid (16 mg) and DMAP (3 mg) were added and kept at room temperature for 2 d, then purified by CC on silica gel (*n*-hexane–EtOAc 4 : 1) to afford *p*-bromobenzoate **16** (14.3 mg).

***p*-Bromobenzoate 16:** ¹H-NMR (400 MHz, CDCl₃): δ 0.88 (3H, s), 0.93 (3H, s), 0.94 (3H, s), 0.97 (3H, s), 2.10 (1H, m), 2.31 (2H, d, $J=2.9$ Hz), 2.46 (1H, m), 3.40 (1H, br d, $J=10.6$ Hz), 3.50 (1H, t, $J=10.6$ Hz), 3.80 (1H, dd, $J=11.0$, 1.8 Hz), 4.98 (1H, dd, $J=10.6$, 6.2 Hz), 5.43 (1H, m), 7.58 (2H, d, $J=8.8$ Hz), 7.91 (2H, d, $J=8.8$ Hz). FAB-MS (*m*-NBA) m/z : 547 [M+2+Na]⁺, 545 [M+Na]⁺; (*m*-NBA+KCl) m/z 563 [M+2+K]⁺, 561 [M+K]⁺. Crystal data: C₂₇H₃₆BrClO₃, Mr=523.944, Triclinic, P_1 , $a=9.9650(5)$ Å, $b=10.0940(6)$ Å, $c=14.6560(13)$ Å, $\alpha=94.54^\circ$, $\beta=94.953(2)^\circ$, $\gamma=114.927(3)^\circ$, $V=1321.0(2)$ Å³, MoK α radiation, $\lambda=0.71073$, DIP Image plate, Refinement on F^2 , full matrix least squares refinement, $R(\text{gt})=0.053$, $wR(\text{gt})=0.1379$, $S(\text{ref})=1.073$, 7592 reflections, 577 parameters, only coordinates of H atoms refined, calculated weights calc, cell refinement: Scalepack (HKL), data reduction: maXus, program used to solve structure: SHELXS-97, Program used to refine structure: SHELXS-97.

Acknowledgments We thank Dr. M. Tanaka (TBU) and Miss Y. Okamoto (TBU) for measurements of NMR and mass spectra. Thanks are also due to Prof. J. E. Braggins (The Auckland University) for the identification of the species. This work was supported by a Grant-in-Aid for Scientific Research (A) (No. 11309012) from the Ministry of Education, Culture, Sports, Science and Technology.

References

- Asakawa Y., "Progress in the Chemistry of Organic Natural Products," Vol. 42, ed. by Herz W., Grisebach H., Kirby G. W., Springer Verlag, Vienna, 1982, pp. 1–285.
- Asakawa Y., "Progress in the Chemistry of Organic Natural Products," Vol. 65, ed. by Herz W., Grisebach H., Kirby G. W., Moore R. E., Steglich W., Tamm Ch., Springer Verlag, Vienna, 1995, pp. 1–562.
- Asakawa Y., Toyota M., Konrat M., Braggins J. E., *Phytochemistry*, **62**, 439–452 (2003).
- Nagashima F., Kasai W., Kondoh M., Fujii M., Watanabe Y., Braggins J. E., Asakawa Y., *Chem. Pharm. Bull.*, **51**, 1189–1192 (2003).
- Allison K. W., Child J., "The Liverworts of New Zealand," University of Otago Press, Dunedin, 1975, pp. 1–300.
- Kim Y.-H., Chung B. S., Sankawa U., *J. Nat. Prod.*, **51**, 1080–1083 (1988).
- Yagi A., Okamura N., Haraguchi Y., Noda K., Nishioka I., *Chem. Pharm. Bull.*, **26**, 1798–1802 (1978).
- Asakawa Y., Toyota M., Takemoto T., *Phytochemistry*, **19**, 2141–2145 (1980).
- Takeda Y., Fatope M. O., *J. Nat. Prod.*, **51**, 725–729 (1988).
- Brown G. D., *J. Nat. Prod.*, **55**, 1756–1760 (1992).
- Lorimer S. D., Perry N. B., *Planta Med.*, **60**, 386–387 (1994).
- Tori M., Masuya T., Asakawa Y., *J. Chem. Res. S*, **1990**, 36–37 (1990).
- Asakawa Y., Toyota M., Matsuda R., Takikawa K., Takemoto T., *Phytochemistry*, **22**, 1413–1415 (1983).
- Scher J. M., Burgess E. J., Lorimer S. D., Perry N. B., *Tetrahedron*, **58**, 7875–7882 (2002).
- Godin P., *Nature* (London), **174**, 134 (1954).